Nyxoah News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

10.06.21	Nyxoah files Registration Statement for Proposed Initial Public Offering in the United States (GlobeNewswire)
07.06.21	Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints (GlobeNewswire)
26.05.21	Publication relating to a transparency notification (GlobeNewswire)
07.05.21	Invitation to attend the annual shareholders’ meeting of the Company to be held on 9 June 2021 (GlobeNewswire)
19.04.21	Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States (GlobeNewswire)
09.04.21	Nyxoah Reports Full Year 2020 Results (GlobeNewswire)
02.04.21	Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021 (GlobeNewswire)
03.03.21	Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC) (GlobeNewswire)
25.02.21	Information on the total number of voting rights and shares (GlobeNewswire)
24.02.21	Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
09.02.21	Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) (GlobeNewswire)
02.02.21	Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA) (GlobeNewswire)
26.01.21	Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) (GlobeNewswire)
05.01.21	First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA) (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V